

Approved



Cambodia
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		2,663,035	5,000,000	7,663,035	0	7,663,035
HHS/CDC	877,808	3,421,657		4,299,465	0	4,299,465
HHS/HRSA		37,500		37,500	0	37,500
Total	877,808	6,122,192	5,000,000	12,000,000	0	12,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	HHS/CDC	HHS/HRSA	USAID		
HBHC	108,987		688,131	0	797,118
HLAB	462,093			0	462,093
HMBL	18,769			0	18,769
HMIN	84,579	37,500		0	122,079
HTXS	344,927		1,846,961	0	2,191,888
HVCT	318,790		1,775,938	0	2,094,728
HVMS	1,631,863		605,083	0	2,236,946
HVOP			772,995	0	772,995
HVSI	649,421		744,278	0	1,393,699
HVTB	221,508		126,536	0	348,044
IDUP			52,142	0	52,142
MTCT	167,491		50,000	0	217,491
OHSS	123,819		759,187	0	883,006
PDCS	28,609		50,000	0	78,609
PDTX	138,609		191,784	0	330,393

Approved



	4,299,465	37,500	7,663,035	0	12,000,000
--	------------------	---------------	------------------	----------	-------------------



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	724,090	0
HVTB	200,000	0
PDCS	50,000	0
Total Technical Area Planned Funding:	974,090	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	226,000	0
HVSI	972,500	0
OHSS	695,000	0
Total Technical Area Planned Funding:	1,893,500	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMIN	76,965	0
HVCT	1,899,090	0
HVOP	708,639	0
IDUP	50,000	0
MTCT	182,000	0
Total Technical Area Planned Funding:	2,916,694	0

Technical Area: Treatment

Approved



Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	2,055,022	0
PDTX	297,500	0
Total Technical Area Planned Funding:	2,352,522	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,892
	Total estimated number of key population in the catchment area	16,300
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,718
	By key population type:	



	<p>Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>240</p>
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>3,493</p>
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>366</p>
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV</p>	<p>75</p>



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,547
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	687
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	10,576
	By key population type: Males who	407



	inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	83
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or	15,843



	meet the minimum standards required	
	Total estimated number of key population in the catchment area	28,637
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,032
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	24,403
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the	



	catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,530
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that	1,281



	are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	10,958
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,600
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	



	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,264
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
Test Result by Age and Sex: Positive: 25-49 Male		
Test Result by Age and Sex:		



	Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH	



	HQ PERMISSION ONLY: 15+ Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	98
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	72
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	2,664
	Service Delivery Point	



	(Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	3,600
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB	



	Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by	



	Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	45,058
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male		
Test Result by Age and Sex: Positive: 25-49 Male		



	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	



	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	13
	Test Result by Aggregated Age and Sex: Positive 15+ Male	859
	Test Result by Aggregated Age and Sex: Positive <15 Female	19
	Test Result by Aggregated Age and Sex: Positive 15+ Female	857
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	



	Service Delivery Point (Community): Mobile testing	5,634
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	38,405
	Service Delivery Point (Facility): VMMC	



	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
	Total number of registered new and relapsed TB cases, during the reporting period.	0
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	



	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during</p>	



	the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+	



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic	



	test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	0
	Sum of Infant Age disaggregates	0
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	997
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	575
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	



	Aggregated Age/Sex: 15+ Female	422
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	997
	Sum of Aggregated Age/Sex disaggregates	997
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	18,020
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	



	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	360
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	8,252
	Aggregated Age/Sex: <15 Female	336
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	9,072
	Sum of Aggregated Age/Sex <15	696
	Sum of Aggregated Age/Sex 15+	17,324
	Sum of Aggregated Age/Sex disaggregates	18,020
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	108
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	57
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	51
	Sum of Aggregated Age/Sex disaggregates	108
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,212
	By Age/Sex: <1	



	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	31
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,009
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	31
	Aggregated Grouping by Age/Sex: 1-14 Female	



	Aggregated Grouping by Age/Sex: 15+ Female	1,141
	Sum of Aggregated Age/Sex disaggregates	2,212
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	762
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	798
	Numerator: Indication: Routine	739
	Numerator: Indication: Targeted	23
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication:	



	<1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication:	



	25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by	



	Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	409
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	353
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,785
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,954



	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	



	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	13,369
	Numerator: Indication: Targeted	416
	Numerator: Preg/BF by Indication: Breastfeeding Routine	



	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	8,852
	Denominator: Indication: Targeted	273
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	



	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	



	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	258
	Numerator Aggregated Age/Sex: 15+ Male	6,336
	Numerator Aggregated Age/Sex: <15 Female	244
	Numerator Aggregated Age/Sex: 15+ Female	6,947
	Denominator Aggregated Age/Sex: <15 Male	286
	Denominator Aggregated Age/Sex: 15+ Male	4,029
	Denominator Aggregated Age/Sex: <15 Female	269
	Denominator Aggregated Age/Sex: 15+ Female	4,903
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at	108



	12 months after initiating ART	
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	120
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at	



	12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	



	period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator:	



	<p>Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,</p>	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	



	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	63
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,127
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,299



	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and	



	children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and	21



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	397
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	349
	Aggregated Age/Sex: <15 Female (Denominator: Total number of	23



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>434</p>



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
13591	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	985,000
14179	Khmer HIV/AIDS NGO Alliance	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	4,974,841
14263	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	149,465
16631	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-USAID	250,000
16632	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	250,000
16681	National Tuberculosis and Leprosy Control Program	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
16683	National Institute of Public Health	Host Country Government	U.S. Department of Health and	GHP-State	160,000



		Agency	Human Services/Centers for Disease Control and Prevention		
16688	National Centre for HIV/AIDS, Dermatology and STDs	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP, GHP-State	840,000
17570	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-USAID	140,000
17797	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-USAID	200,000
18152	American International Health Alliance	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	37,500



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 13591	Mechanism Name: HIV Innovate and Evaluate
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 985,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 985,000	
Funding Source	Funding Amount
GHP-USAID	985,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	179,090
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	179,094
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs

Budget Code Information



Mechanism ID: 13591			
Mechanism Name: HIV Innovate and Evaluate			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	179,090	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	179,090	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	268,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	358,181	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14179	Mechanism Name: KHANA Flagship
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Khmer HIV/AIDS NGO Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,974,841	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,974,841	
Funding Source	Funding Amount
GHP-State	2,663,035
GHP-USAID	2,311,806



Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,690,000
Key Populations: MSM and TG	1,417,500
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	708,750
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	300,000
Focus Area:	Equity in HIV prevention, care, treatment and support



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 14179			
Mechanism Name: KHANA Flagship			
Prime Partner Name: Khmer HIV/AIDS NGO Alliance			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	495,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	467,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,575,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	440,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,454,841	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	187,500	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,892
KP_PREV_DSD	Total estimated number of key population in the catchment area	16,300
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,718
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	240



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,493
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	366
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	75
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,547
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	687
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	10,576
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	407
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	83
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	15,843



KP_PREV_TA	Total estimated number of key population in the catchment area	36,961
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,032
KP_PREV_TA	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	24,403
KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,530
KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,281
KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	10,958
KP_PREV_TA	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,600
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,264
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	98
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	72
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	2,664



HTC_TST_DSD	Service Delivery Point (Facility): VCT	3,600
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,905
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	551
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	516
HTC_TST_TA	Service Delivery Point (Community): Mobile testing	6,653
HTC_TST_TA	Service Delivery Point (Facility): VCT	30,252
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	997
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	575
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	422
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	997
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	997
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,286
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	3,762
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,524
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,286
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,286
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	108
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	57
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	51
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	108
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,020
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	526
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	494
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,020
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	762



	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	798
TX_PVLS_DSD	Numerator: Indication: Routine	739
TX_PVLS_DSD	Numerator: Indication: Targeted	23
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	409
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	353
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,574
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,829
TX_PVLS_TA	Numerator: Indication: Routine	5,406
TX_PVLS_TA	Numerator: Indication: Targeted	168
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,879
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,695
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	186
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	176
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	108
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	120
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	63
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	45



	treatment at 12 months after initiating ART)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	421
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	468
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29

Implementing Mechanism Details

Mechanism ID: 14263	Mechanism Name: Kingdom of Cambodia Ministry of Health - MOH CoAg Phase II
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 149,465	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 149,465	
Funding Source	Funding Amount
GHP-State	149,465

Cross-Cutting Budget Attribution(s)

Human Resources for Health	25,000
----------------------------	--------



Budget Code Information

Mechanism ID: 14263			
Mechanism Name: Kingdom of Cambodia Ministry of Health - MOH CoAg Phase II			
Prime Partner Name: Ministry of Health (MOH)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	39,465	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16631	Mechanism Name: Health Information, Policy, and Advocacy (HIPA) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount



GHP-USAID	250,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16631		
Mechanism Name:	Health Information, Policy, and Advocacy (HIPA) Project		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16632	Mechanism Name: Social Health Protection Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	

Approved



Funding Source	Funding Amount
GHP-USAID	250,000

Cross-Cutting Budget Attribution(s)

Economic Strengthening	250,000
------------------------	---------

Budget Code Information

Mechanism ID:	16632		
Mechanism Name:	Social Health Protection Program		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16681	Mechanism Name: National Center for Tuberculosis and Leprosy Control (CENAT) Phase II
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Tuberculosis and Leprosy Control Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 150,000	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	15,000
----------------------------	--------

Budget Code Information

Mechanism ID:	16681		
Mechanism Name:	National Center for Tuberculosis and Leprosy Control (CENAT) Phase II		
Prime Partner Name:	National Tuberculosis and Leprosy Control Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_ART_TA	The number of registered new and relapse TB cases	0



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0

Implementing Mechanism Details

Mechanism ID: 16683	Mechanism Name: National Institute of Public Health Phase III
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Institute of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 160,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 160,000	
Funding Source	Funding Amount
GHP-State	160,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

Budget Code Information

Mechanism ID:	16683		
Mechanism Name:	National Institute of Public Health Phase III		
Prime Partner Name:	National Institute of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	160,000	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16688	Mechanism Name: National Centre for HIV/AIDS, Dermatology and STDs Phase IV
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Centre for HIV/AIDS, Dermatology and STDs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 840,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 840,000	
Funding Source	Funding Amount
GAP	800,000
GHP-State	40,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	300,000
Key Populations: MSM and TG	25,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Key Populations: FSW	25,000
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Collection and use of strategic information on SWs and clients
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	16688		
Mechanism Name:	National Centre for HIV/AIDS, Dermatology and STDs Phase IV		
Prime Partner Name:	National Centre for HIV/AIDS, Dermatology and STDs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	66,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	145,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	145,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	82,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	242,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	110,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,153
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	13
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	326
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	19
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	346
HTC_TST_TA	Service Delivery Point (Facility): VCT	8,153
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	0
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,734
TX_CURR_TA	Aggregated Age/Sex: <15 Male	360
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,490



TX_CURR_TA	Aggregated Age/Sex: <15 Female	336
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,548
TX_CURR_TA	Sum of Aggregated Age/Sex <15	696
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	10,038
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,734
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,192
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	31
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	483
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	31
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	647
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,192
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,211
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	9,125
TX_PVLS_TA	Numerator: Indication: Routine	7,963
TX_PVLS_TA	Numerator: Indication: Targeted	248
TX_PVLS_TA	Denominator: Indication: Routine	8,852
TX_PVLS_TA	Denominator: Indication: Targeted	273
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	258
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	3,457
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	244
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	4,252
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	286
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,843
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	269
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	4,727
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	706



TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	831
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	297
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	368
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	349
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	434



	stopped ART, and those lost to follow-up)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 17570	Mechanism Name: Global Health Supply Chain - Procurement and Supply Management
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 140,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 140,000	
Funding Source	Funding Amount
GHP-USAID	140,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17570		
Mechanism Name:	Global Health Supply Chain - Procurement and Supply Management		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	140,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17797	Mechanism Name: Health Financing and Governance Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-USAID	200,000

Cross-Cutting Budget Attribution(s)

Economic Strengthening	200,000
------------------------	---------

Budget Code Information

Mechanism ID: 17797			
Mechanism Name: Health Financing and Governance Project			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18152	Mechanism Name: Twinning Initiative
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 37,500	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 37,500	
Funding Source	Funding Amount
GHP-State	37,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18152		
Mechanism Name:	Twinning Initiative		
Prime Partner Name:	American International Health Alliance		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	37,500	0

Implementing Mechanism Indicator Information



(No data provided.)

**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services			34,528	0	34,528	34,528
ICASS			112,215	0	112,215	112,215
Management Meetings/Professional Development			60,424	0	60,424	60,424
Non-ICASS Administrative Costs			189,903	0	189,903	189,903
Staff Program Travel			77,688	0	77,688	77,688
USG Staff Salaries and Benefits - Internationally Recruited			287,444	0	287,444	287,444
USG Staff Salaries and Benefits - Locally Recruited			100,992	0	100,992	100,992



Total	0	0	863,194	0	863,194	863,194
--------------	----------	----------	----------------	----------	----------------	----------------

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		127,000		0	127,000	127,000
Computers/IT Services		30,000		0	30,000	30,000
ICASS	77,808	492,192		0	570,000	570,000
Institutional Contractors		100,000		0	100,000	100,000
Management Meetings/Professional Development		21,375		0	21,375	21,375
Non-ICASS Administrative Costs		316,359		0	316,359	316,359
Non-ICASS Motor Vehicles		50,000		0	50,000	50,000
Staff Program Travel		196,125		0	196,125	196,125
USG Staff Salaries and Benefits -		1,098,725		0	1,098,725	1,098,725

Approved



Internationally Recruited						
USG Staff Salaries and Benefits - Locally Recruited		490,416		0	490,416	490,416
Total	77,808	2,922,192	0	0	3,000,000	3,000,000